Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | ESRRG | P62508 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27670147 | 0.90 | MAOB (0.52) | GAAEPHX2NR1H4GRIN2DGRIN3B | |
| SCHEMBL4250202 | 0.89 | GAA (0.52) | GAAGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4243512 | 0.87 | GAA (0.55) | GAAGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4244744 | 0.86 | PARP10 (0.53) | GAA | |
| SCHEMBL4239619 | 0.86 | GAA (0.65) | GAAGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4768629 | 0.86 | GAA (0.67) | GAA | |
| SCHEMBL4243148 | 0.85 | GAA (0.55) | GAAGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4247873 | 0.85 | GAA (0.58) | GAAGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4241028 | 0.84 | MEN1 (0.53) | GAAGRIN1GRIN2B | |
| SCHEMBL1008518 | 0.82 | GRIN2D (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170901-A1 | Benzoyl Urea Derivatives | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2009-07-02 | — | — | US | disclosed |
| EP-1771429-A1 | NEW BENZOYL UREA DERIVATIVES | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006010966-A1 | NEW BENZOYL UREA DERIVATIVES | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170901-A1 | Benzoyl Urea Derivatives | OPRM1, GRIN2C, GRIN3A | GAA 3604/4885EPHX2 1860/4885NR1H4 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.